Annovis Bio Stock Price Drops 8.5% - What's Next?

Shares of the biotech company fell amid market volatility.

Published on Mar. 6, 2026

Got story updates? Submit your updates here. ›

Annovis Bio, Inc. (NYSE:ANVS) saw its stock price decline by 8.5% during mid-day trading on Thursday, with shares trading as low as $2.42 before closing at $2.47. Trading volume was down 27% from the average daily volume. The company, which is focused on developing treatments for neurodegenerative disorders, has a market capitalization of $65.46 million.

Why it matters

The drop in Annovis Bio's stock price reflects broader market volatility, as investors remain cautious about the outlook for biotechnology companies. However, the company's pipeline of potential treatments for Alzheimer's, Parkinson's, and other central nervous system conditions continues to generate interest from analysts and investors.

The details

Annovis Bio's stock decline came amid a broader sell-off in the market, with the company's shares trading down along with other biotech and pharmaceutical stocks. Wall Street analysts have a mixed view on the company, with one rating it a 'sell', one a 'hold', and two a 'buy'. The company's lead asset, ANVS401 (Posiphen®), is currently in clinical trials to evaluate its ability to reduce levels of amyloid precursor protein and its toxic fragments in Alzheimer's patients.

  • Annovis Bio's stock price fell 8.5% during mid-day trading on Thursday, March 6, 2026.
  • The stock traded as low as $2.42 and closed at $2.47 on the day.

The players

Annovis Bio, Inc.

A clinical-stage biotechnology company focused on developing treatments for neurodegenerative and neuroinflammatory disorders.

ANVS401 (Posiphen®)

Annovis Bio's lead asset, an oral small molecule that has been evaluated in Phase 1 and Phase 2 clinical trials to reduce levels of amyloid precursor protein and its toxic fragments in Alzheimer's patients.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

The takeaway

The drop in Annovis Bio's stock price reflects the volatility in the biotech sector, but the company's pipeline of potential treatments for neurodegenerative disorders continues to generate interest from analysts and investors. As the company progresses its clinical trials, investors will be closely watching for updates on the development of ANVS401 and the company's broader strategy.